Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Diabetic Gastroenteropathy: Soothe the Symptoms or Unravel a Cure?

Author(s): Sondre Meling*, Davide Bertoli, Dag A. Sangnes, Christina Brock, Asbjørn Drewes, Niels Ejskjaer, Georg Dimcevski and Eirik Søfteland

Volume 18, Issue 5, 2022

Published on: 22 March, 2021

Article ID: e220321192412 Pages: 22

DOI: 10.2174/1573399817666210322154618

Abstract

Autonomic neuropathy in patients with diabetes mellitus, and especially complications related to gastrointestinal neuropathy, are often overlooked in the clinic. Diabetic gastroenteropathy affects every segment of the gastrointestinal tract and generates symptoms that may include nausea, early satiety, vomiting, abdominal pain, constipation, and diarrhea. Severe cases can be complicated by weight loss, dehydration, and electrolyte disturbances. The pathophysiology is complex, the diagnostics and treatment options are multidisciplinary, and there is generally a lack of evidence for the treatment options. The aims for this review are first to summarize the pathophysiology and describe possible and expected symptoms and complications.Further, we will try to supply the clinician with a straightforward tool for diagnostics, and then, we shall summarize established treatment options, including diet recommendations, pharmacological and non-pharmacological options. Finally, we will explore the multiple possibilities of novel treatment, looking at medications related to the pathophysiology of neuropathy, other manifestations of autonomic neuropathies, and symptomatic treatment for other gastrointestinal disorders, also including new knowledge of endosurgical and neuromodulatory treatment. The overall goal is to increase awareness and knowledge on this frequent diabetic complication and to provide better tools for diagnosis and treatment. Ultimately, we hope to encourage further research in this field, as there are clear shortcomings in terms of biomarkers, pathophysiology, as well as treatment possibilities. In conclusion, diagnosis and management of diabetic gastroenteropathy are challenging and often require multidisciplinary teams and multimodal therapies. Treatment options are sparse, but new pharmacological, endoscopic, and neuromodulatory techniques have shown promising results in initial studies.

Keywords: Diabetes mellitus, autonomic neuropathy, diabetic gastroenteropathy, diagnostics, novel treatment, pharmacological, endo-surgical, neuromodulation.

[1]
Du YT, Rayner CK, Jones KL, Talley NJ, Horowitz M. Gastrointestinal symptoms in diabetes: prevalence, assessment, pathogenesis, and management. Diabetes Care 2018; 41(3): 627-37.
[http://dx.doi.org/10.2337/dc17-1536] [PMID: 29463666]
[2]
Rudchenko A, Akude E, Cooper E. Synapses on sympathetic neurons and parasympathetic neurons differ in their vulnerability to diabetes. J Neurosci 2014; 34(26): 8865-74.
[http://dx.doi.org/10.1523/JNEUROSCI.0033-14.2014] [PMID: 24966386]
[3]
Furness JB, Kunze WA, Bertrand PP, Clerc N, Bornstein JC. Intrinsic primary afferent neurons of the intestine. Prog Neurobiol 1998; 54(1): 1-18.
[http://dx.doi.org/10.1016/S0301-0082(97)00051-8] [PMID: 9460790]
[4]
Furness JB. The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol 2012; 9(5): 286-94.
[http://dx.doi.org/10.1038/nrgastro.2012.32] [PMID: 22392290]
[5]
Gómez O, Ballester-Lurbe B, Poch E, Mesonero JE, Terrado J. Developmental regulation of glucose transporters GLUT3, GLUT4 and GLUT8 in the mouse cerebellar cortex. J Anat 2010; 217(5): 616-23.
[http://dx.doi.org/10.1111/j.1469-7580.2010.01291.x] [PMID: 20819112]
[6]
Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci 2008; 9(1): 36-45.
[http://dx.doi.org/10.1038/nrn2294] [PMID: 18094705]
[7]
Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res 2016; 118(11): 1808-29.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.306923] [PMID: 27230643]
[8]
Juranek J, Ray R, Banach M, Rai V. Receptor for advanced glycation end-products in neurodegenerative diseases. Rev Neurosci 2015; 26(6): 691-8.
[http://dx.doi.org/10.1515/revneuro-2015-0003] [PMID: 26226128]
[9]
Slyepchenko A, Maes M, Machado-Vieira R, et al. Intestinal dysbiosis, gut hyperpermeability and bacterial translocation: missing links between depression, obesity and type 2 diabetes. Curr Pharm Des 2016; 22(40): 6087-106.
[http://dx.doi.org/10.2174/1381612822666160922165706] [PMID: 27669970]
[10]
Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Benef Microbes 2014; 5(1): 3-17.
[http://dx.doi.org/10.3920/BM2012.0065] [PMID: 23886976]
[11]
Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013; 498(7452): 99-103.
[http://dx.doi.org/10.1038/nature12198] [PMID: 23719380]
[12]
Zhang X, Shen D, Fang Z, et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One 2013; 8(8): e71108.
[http://dx.doi.org/10.1371/journal.pone.0071108] [PMID: 24013136]
[13]
Amar J, Serino M, Lange C, et al. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia 2011; 54(12): 3055-61.
[http://dx.doi.org/10.1007/s00125-011-2329-8] [PMID: 21976140]
[14]
Pussinen PJ, Havulinna AS, Lehto M, Sundvall J, Salomaa V. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 2011; 34(2): 392-7.
[http://dx.doi.org/10.2337/dc10-1676] [PMID: 21270197]
[15]
Bordalo Tonucci L, Dos Santos KM, De Luces Fortes Ferreira CL, Ribeiro SM, De Oliveira LL, Martino HS. Gut microbiota and probiotics: Focus on diabetes mellitus. Crit Rev Food Sci Nutr 2017; 57(11): 2296-309.
[http://dx.doi.org/10.1080/10408398.2014.934438] [PMID: 26499995]
[16]
Chandrasekharan B, Jeppsson S, Pienkowski S, et al. Tumor necrosis factor-neuropeptide Y cross talk regulates inflammation, epithelial barrier functions, and colonic motility. Inflamm Bowel Dis 2013; 19(12): 2535-46.
[http://dx.doi.org/10.1097/01.MIB.0000437042.59208.9f] [PMID: 24108115]
[17]
Choi KM, Gibbons SJ, Nguyen TV, et al. Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. Gastroenterology 2008; 135(6): 2055-2064, 2064.e1-2064.e2.
[http://dx.doi.org/10.1053/j.gastro.2008.09.003] [PMID: 18926825]
[18]
Kindt S, Vanden Berghe P, Boesmans W, Roosen L, Tack J. Prolonged IL-1beta exposure alters neurotransmitter and electrically induced Ca(2+) responses in the myenteric plexus. Neurogastroenterol Motil 2010; 22(3): 321-e85.
[http://dx.doi.org/10.1111/j.1365-2982.2009.01414.x] [PMID: 19796332]
[19]
Brierley SM, Linden DR. Neuroplasticity and dysfunction after gastrointestinal inflammation. Nat Rev Gastroenterol Hepatol 2014; 11(10): 611-27.
[http://dx.doi.org/10.1038/nrgastro.2014.103] [PMID: 25001973]
[20]
Aubé AC, Cabarrocas J, Bauer J, et al. Changes in enteric neurone phenotype and intestinal functions in a transgenic mouse model of enteric glia disruption. Gut 2006; 55(5): 630-7.
[http://dx.doi.org/10.1136/gut.2005.067595] [PMID: 16236773]
[21]
Ochoa-Cortes F, Turco F, Linan-Rico A, et al. Enteric Glial Cells: A new frontier in neurogastroenterology and clinical target for inflammatory bowel diseases. Inflamm Bowel Dis 2016; 22(2): 433-49.
[http://dx.doi.org/10.1097/MIB.0000000000000667] [PMID: 26689598]
[22]
Anitha M, Gondha C, Sutliff R, et al. GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway. J Clin Invest 2006; 116(2): 344-56.
[http://dx.doi.org/10.1172/JCI26295] [PMID: 16453021]
[23]
Thaiss CA, Levy M, Grosheva I, et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science 2018; 359(6382): 1376-83.
[http://dx.doi.org/10.1126/science.aar3318] [PMID: 29519916]
[24]
Zawada AE, Moszak M, Skrzypczak D, Grzymisławski M. Gastrointestinal complications in patients with diabetes mellitus. Adv Clin Exp Med 2018; 27(4): 567-72.
[http://dx.doi.org/10.17219/acem/67961] [PMID: 29533548]
[25]
Monckton G, Pehowich E. Autonomic neuropathy in the streptozotocin diabetic rat. Can J Neurol Sci 1980; 7(2): 135-42.
[http://dx.doi.org/10.1017/S0317167100023519] [PMID: 6447537]
[26]
Chandrasekharan B, Anitha M, Blatt R, et al. Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress. Neurogastroenterol Motil 2011; 23(2): 131-138, e26.
[http://dx.doi.org/10.1111/j.1365-2982.2010.01611.x] [PMID: 20939847]
[27]
Gotfried J, Priest S, Schey R. Diabetes and the small intestine. Curr Treat Options Gastroenterol 2017; 15(4): 490-507.
[http://dx.doi.org/10.1007/s11938-017-0155-x] [PMID: 28913777]
[28]
Iwasaki H, Kajimura M, Osawa S, et al. A deficiency of gastric interstitial cells of Cajal accompanied by decreased expression of neuronal nitric oxide synthase and substance P in patients with type 2 diabetes mellitus. J Gastroenterol 2006; 41(11): 1076-87.
[http://dx.doi.org/10.1007/s00535-006-1909-8] [PMID: 17160518]
[29]
Bódi N, Talapka P, Poles MZ, et al. Gut region-specific diabetic damage to the capillary endothelium adjacent to the myenteric plexus. Microcirculation 2012; 19(4): 316-26.
[http://dx.doi.org/10.1111/j.1549-8719.2012.00164.x] [PMID: 22296580]
[30]
Horváth VJ, Vittal H, Lörincz A, et al. Reduced stem cell factor links smooth myopathy and loss of interstitial cells of cajal in murine diabetic gastroparesis. Gastroenterology 2006; 130(3): 759-70.
[http://dx.doi.org/10.1053/j.gastro.2005.12.027] [PMID: 16530517]
[31]
Frøkjaer JB, Søfteland E, Graversen C, et al. Central processing of gut pain in diabetic patients with gastrointestinal symptoms. Diabetes Care 2009; 32(7): 1274-7.
[http://dx.doi.org/10.2337/dc09-0324] [PMID: 19366960]
[32]
Parkman HP, Camilleri M, Farrugia G, et al. Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterol Motil 2010; 22(2): 113-33.
[http://dx.doi.org/10.1111/j.1365-2982.2009.01434.x] [PMID: 20003077]
[33]
Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: A population-based survey of 15,000 adults. Arch Intern Med 2001; 161(16): 1989-96.
[http://dx.doi.org/10.1001/archinte.161.16.1989] [PMID: 11525701]
[34]
Talley SJ, Bytzer P, Hammer J, Young L, Jones M, Horowitz M. Psychological distress is linked to gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol 2001; 96(4): 1033-8.
[http://dx.doi.org/10.1111/j.1572-0241.2001.03605.x] [PMID: 11316143]
[35]
Teigland T, Iversen MM, Sangnes DA, Dimcevski G, Søfteland E. A longitudinal study on patients with diabetes and symptoms of gastroparesis - associations with impaired quality of life and increased depressive and anxiety symptoms. J Diabetes Complications 2018; 32(1): 89-94.
[http://dx.doi.org/10.1016/j.jdiacomp.2017.10.010] [PMID: 29153755]
[36]
Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol 2011; 9(12): 1056-64.
[http://dx.doi.org/10.1016/j.cgh.2011.08.013] [PMID: 21871247]
[37]
Quan C, Talley NJ, Jones MP, Spies J, Horowitz M. Gain and loss of gastrointestinal symptoms in diabetes mellitus: Associations with psychiatric disease, glycemic control, and autonomic neuropathy over 2 years of follow-up. Am J Gastroenterol 2008; 103(8): 2023-30.
[http://dx.doi.org/10.1111/j.1572-0241.2008.01943.x] [PMID: 18796098]
[38]
Sangnes DA, Søfteland E, Bekkelund M, et al. Wireless motility capsule compared with scintigraphy in the assessment of diabetic gastroparesis. Neurogastroenterol Motil 2020; 32(4): e13771.
[http://dx.doi.org/10.1111/nmo.13771] [PMID: 31886950]
[39]
Sangnes DA, Søfteland E, Teigland T, Dimcevski G. Comparing radiopaque markers and 13C-labelled breath test in diabetic gastroparesis diagnostics. Clin Exp Gastroenterol 2019; 12: 193-201.
[http://dx.doi.org/10.2147/CEG.S200875] [PMID: 31190946]
[40]
Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: A joint report of the american neurogastroenterology and motility society and the society of nuclear medicine. J Nucl Med Technol 2008; 36(1): 44-54.
[http://dx.doi.org/10.2967/jnmt.107.048116] [PMID: 18287197]
[41]
Bharucha AE, Batey-Schaefer B, Cleary PA, et al. Delayed gastric emptying is associated with early and long-term hyperglycemia in type 1 diabetes mellitus. Gastroenterology 2015; 149(2): 330-9.
[http://dx.doi.org/10.1053/j.gastro.2015.05.007] [PMID: 25980755]
[42]
Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33(10): 2285-93.
[http://dx.doi.org/10.2337/dc10-1303] [PMID: 20876709]
[43]
Schvarcz E, Palmér M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997; 113(1): 60-6.
[http://dx.doi.org/10.1016/S0016-5085(97)70080-5] [PMID: 9207262]
[44]
Schvarcz E, Palmér M, Aman J, Lindkvist B, Beckman KW. Hypoglycaemia increases the gastric emptying rate in patients with type 1 diabetes mellitus. Diabet Med 1993; 10(7): 660-3.
[http://dx.doi.org/10.1111/j.1464-5491.1993.tb00141.x] [PMID: 8403829]
[45]
Cherian D, Sachdeva P, Fisher RS, Parkman HP. Abdominal pain is a frequent symptom of gastroparesis. Clin Gastroenterol Hepatol 2010; 8(8): 676-81.
[http://dx.doi.org/10.1016/j.cgh.2010.04.027] [PMID: 20472097]
[46]
Parkman HP, Hallinan EK, Hasler WL, et al. Nausea and vomiting in gastroparesis: Similarities and differences in idiopathic and diabetic gastroparesis. Neurogastroenterol Motil 2016; 28(12): 1902-14.
[http://dx.doi.org/10.1111/nmo.12893] [PMID: 27350152]
[47]
Hoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol 1999; 94(4): 1029-33.
[http://dx.doi.org/10.1111/j.1572-0241.1999.01008.x] [PMID: 10201478]
[48]
Frøkjaer JB, Brock C, Brun J, et al. Esophageal distension parameters as potential biomarkers of impaired gastrointestinal function in diabetes patients. Neurogastroenterol Motil 2012; 24(11): 1016-e544.
[http://dx.doi.org/10.1111/j.1365-2982.2012.01966.x] [PMID: 22738347]
[49]
Hasler WL, Wilson LA, Parkman HP, et al. Bloating in gastroparesis: Severity, impact, and associated factors. Am J Gastroenterol 2011; 106(8): 1492-502.
[http://dx.doi.org/10.1038/ajg.2011.81] [PMID: 21483459]
[50]
Parkman HP, Wilson LA, Hasler WL, et al. Abdominal pain in patients with gastroparesis: Associations with gastroparesis symptoms, etiology of gastroparesis, gastric emptying, somatization, and quality of life. Dig Dis Sci 2019; 64(8): 2242-55.
[http://dx.doi.org/10.1007/s10620-019-05522-9] [PMID: 30852767]
[51]
Brock C, Søfteland E, Gunterberg V, et al. Diabetic autonomic neuropathy affects symptom generation and brain-gut axis. Diabetes Care 2013; 36(11): 3698-705.
[http://dx.doi.org/10.2337/dc13-0347] [PMID: 24026548]
[52]
Frøkjær JB, Due Andersen S, Ejskjær N, et al. Gut sensations in diabetic autonomic neuropathy. Pain 2007; 131(3): 320-9.
[http://dx.doi.org/10.1016/j.pain.2007.04.009] [PMID: 17521809]
[53]
Brock C, Graversen C, Frøkjaer JB, Søfteland E, Valeriani M, Drewes AM. Peripheral and central nervous contribution to gastrointestinal symptoms in diabetic patients with autonomic neuropathy. Eur J Pain 2013; 17(6): 820-31.
[http://dx.doi.org/10.1002/j.1532-2149.2012.00254.x] [PMID: 23239083]
[54]
Frøkjær JB, Egsgaard LL, Graversen C, et al. Gastrointestinal symptoms in type-1 diabetes: is it all about brain plasticity? Eur J Pain 2011; 15(3): 249-57.
[http://dx.doi.org/10.1016/j.ejpain.2010.08.004] [PMID: 20813568]
[55]
Selby A, Reichenbach ZW, Piech G, Friedenberg FK. Pathophysiology, differential diagnosis, and treatment of diabetic diarrhea. Dig Dis Sci 2019; 64(12): 3385-93.
[http://dx.doi.org/10.1007/s10620-019-05846-6] [PMID: 31541370]
[56]
Brock C, Drewes AM, Farmer AD. Multiregional dysmotility in diabetes mellitus assessed using the wireless motility capsule. Neurogastroenterol Motil 2017; 29(9)
[http://dx.doi.org/10.1111/nmo.13135] [PMID: 28782196]
[57]
Wald A. Incontinence and anorectal dysfunction in patients with diabetes mellitus. Eur J Gastroenterol Hepatol 1995; 7(8): 737-9.
[PMID: 7496860]
[58]
Søfteland E, Brock C, Frøkjær JB, et al. Association between visceral, cardiac and sensorimotor polyneuropathies in diabetes mellitus. J Diabetes Complications 2014; 28(3): 370-7.
[http://dx.doi.org/10.1016/j.jdiacomp.2013.10.009] [PMID: 24355661]
[59]
Ihana-Sugiyama N, Nagata N, Yamamoto-Honda R, et al. Constipation, hard stools, fecal urgency, and incomplete evacuation, but not diarrhea is associated with diabetes and its related factors. World J Gastroenterol 2016; 22(11): 3252-60.
[http://dx.doi.org/10.3748/wjg.v22.i11.3252] [PMID: 27004003]
[60]
Sommers T, Mitsuhashi S, Singh P, et al. Prevalence of chronic constipation and chronic diarrhea in diabetic individuals in the United States. Am J Gastroenterol 2019; 114(1): 135-42.
[http://dx.doi.org/10.1038/s41395-018-0418-8] [PMID: 30410038]
[61]
Farmer AD, Pedersen AG, Brock B, et al. Type 1 diabetic patients with peripheral neuropathy have pan-enteric prolongation of gastrointestinal transit times and an altered caecal pH profile. Diabetologia 2017; 60(4): 709-18.
[http://dx.doi.org/10.1007/s00125-016-4199-6] [PMID: 28105520]
[62]
Klinge MW, Haase AM, Mark EB, et al. Colonic motility in patients with type 1 diabetes and gastrointestinal symptoms. Neurogastroenterol Motil 2020; 32(12): e13948.
[http://dx.doi.org/10.1111/nmo.13948] [PMID: 32688448]
[63]
Stevens JE, Jones KL, Rayner CK, Horowitz M. Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives. Expert Opin Pharmacother 2013; 14(9): 1171-86.
[http://dx.doi.org/10.1517/14656566.2013.795948] [PMID: 23663133]
[64]
Talley NJ, Young L, Bytzer P, et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am J Gastroenterol 2001; 96(1): 71-6.
[http://dx.doi.org/10.1111/j.1572-0241.2001.03350.x] [PMID: 11197290]
[65]
Maleki D, Locke GR III, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 2000; 160(18): 2808-16.
[http://dx.doi.org/10.1001/archinte.160.18.2808] [PMID: 11025791]
[66]
Bharucha AE, Kudva YC, Prichard DO. Diabetic Gastroparesis. Endocr Rev 2019; 40(5): 1318-52.
[http://dx.doi.org/10.1210/er.2018-00161] [PMID: 31081877]
[67]
Meldgaard T, Keller J, Olesen AE, et al. Pathophysiology and management of diabetic gastroenteropathy. Therap Adv Gastroenterol 2019; 12: 1756284819852047.
[http://dx.doi.org/10.1177/1756284819852047] [PMID: 31244895]
[68]
Sona MF, Myung SK, Park K, Jargalsaikhan G. Type 1 diabetes mellitus and risk of cancer: A meta-analysis of observational studies. Jpn J Clin Oncol 2018; 48(5): 426-33.
[http://dx.doi.org/10.1093/jjco/hyy047] [PMID: 29635473]
[69]
de Jong RGPJ, Peeters PJHL, Burden AM, et al. Gastrointestinal cancer incidence in type 2 diabetes mellitus; results from a large population-based cohort study in the UK. Cancer Epidemiol 2018; 54: 104-11.
[http://dx.doi.org/10.1016/j.canep.2018.04.008] [PMID: 29705628]
[70]
Yuan S, Kar S, Carter P, et al. Is type 2 diabetes causally associated with cancer risk? evidence from a two-sample mendelian randomization study. Diabetes 2020; 69(7): 1588-96.
[http://dx.doi.org/10.2337/db20-0084] [PMID: 32349989]
[71]
Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2017; 19(4): 524-36.
[http://dx.doi.org/10.1111/dom.12849] [PMID: 27981757]
[72]
Philip NA, Ahmed N, Pitchumoni CS. Spectrum of drug-induced chronic diarrhea. J Clin Gastroenterol 2017; 51(2): 111-7.
[http://dx.doi.org/10.1097/MCG.0000000000000752] [PMID: 28027072]
[73]
Parkman HP, Sharkey EP, Nguyen LA, et al. Marijuana use in patients with symptoms of gastroparesis: prevalence, patient characteristics, and perceived benefit. Dig Dis Sci 2020; 65(8): 2311-20.
[http://dx.doi.org/10.1007/s10620-019-05963-2] [PMID: 31758430]
[74]
Husebye ES, Anderson MS, Kämpe O. Autoimmune polyendocrine syndromes. N Engl J Med 2018; 378(12): 1132-41.
[http://dx.doi.org/10.1056/NEJMra1713301] [PMID: 29562162]
[75]
Ebert EC. The thyroid and the gut. J Clin Gastroenterol 2010; 44(6): 402-6.
[http://dx.doi.org/10.1097/MCG.0b013e3181d6bc3e] [PMID: 20351569]
[76]
Erichsen MM, Løvås K, Skinningsrud B, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab 2009; 94(12): 4882-90.
[http://dx.doi.org/10.1210/jc.2009-1368] [PMID: 19858318]
[77]
Maconi G, Furfaro F, Sciurti R, Bezzio C, Ardizzone S, de Franchis R. Glucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implications. World J Gastroenterol 2014; 20(13): 3507-15.
[http://dx.doi.org/10.3748/wjg.v20.i13.3507] [PMID: 24707133]
[78]
Vigren L, Tysk C, Ström M, et al. Celiac disease and other autoimmune diseases in patients with collagenous colitis. Scand J Gastroenterol 2013; 48(8): 944-50.
[http://dx.doi.org/10.3109/00365521.2013.805809] [PMID: 23800241]
[79]
Søfteland E, Poulsen JL, Starup-Linde J, et al. Pancreatic exocrine insufficiency in diabetes mellitus - prevalence and characteristics. Eur J Intern Med 2019; 68: 18-22.
[http://dx.doi.org/10.1016/j.ejim.2019.07.021] [PMID: 31402275]
[80]
Meldgaard T, Olesen SS, Farmer AD, et al. Diabetic enteropathy: from molecule to mechanism-based treatment. J Diabetes Res 2018; 2018: 3827301.
[http://dx.doi.org/10.1155/2018/3827301] [PMID: 30306092]
[81]
Carrington EV, Scott SM, Bharucha A, et al. Expert consensus document: Advances in the evaluation of anorectal function. Nat Rev Gastroenterol Hepatol 2018; 15(5): 309-23.
[http://dx.doi.org/10.1038/nrgastro.2018.27] [PMID: 29636555]
[82]
Savarino E, Bredenoord AJ, Fox M, Pandolfino JE, Roman S, Gyawali CP. Expert consensus document: Advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol 2017; 14(11): 665-76.
[http://dx.doi.org/10.1038/nrgastro.2017.130] [PMID: 28951582]
[83]
Keller J, Bassotti G, Clarke J, et al. Expert consensus document: Advances in the diagnosis and classification of gastric and intestinal motility disorders. Nat Rev Gastroenterol Hepatol 2018; 15(5): 291-308.
[http://dx.doi.org/10.1038/nrgastro.2018.7] [PMID: 29622808]
[84]
Fox MR, Kahrilas PJ, Roman S, et al. Clinical measurement of gastrointestinal motility and function: who, when and which test? Nat Rev Gastroenterol Hepatol 2018; 15(9): 568-79.
[http://dx.doi.org/10.1038/s41575-018-0030-9] [PMID: 29872118]
[85]
Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129(5): 1756-80.
[http://dx.doi.org/10.1053/j.gastro.2005.09.020] [PMID: 16285971]
[86]
Bonis PAL. Approach to the adult with chronic diarrhea in resource-rich settings. 2020.
[87]
Brandt L, Ed. Sleisenger and Fordtran’s gastrointestinal and liver disease.Book: Feldman M, FL. 10th. New York: Elsevier 2015.
[88]
Penner RM. Evaluation of the adult with abdominal pain. 2020.
[89]
Wald A. Etiology and evaluation of chronic constipation in adults. 2020.
[90]
Robson KM. Fecal incontinence in adults: Etiology and evaluation. 2020.
[91]
Camilleri M. Novel diet, drugs, and gastric interventions for gastroparesis. Clin Gastroenterol Hepatol 2016; 14(8): 1072-80.
[http://dx.doi.org/10.1016/j.cgh.2015.12.033] [PMID: 26762845]
[92]
Gentilcore D, O’Donovan D, Jones KL, Horowitz M. Nutrition therapy for diabetic gastroparesis. Curr Diab Rep 2003; 3(5): 418-26.
[http://dx.doi.org/10.1007/s11892-003-0087-9] [PMID: 12975033]
[93]
Sadiya A. Nutritional therapy for the management of diabetic gastroparesis: clinical review. Diabetes Metab Syndr Obes 2012; 5: 329-35.
[http://dx.doi.org/10.2147/DMSO.S31962] [PMID: 23055757]
[94]
Olausson EA, Störsrud S, Grundin H, Isaksson M, Attvall S, Simrén M. A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: A randomized controlled trial. Am J Gastroenterol 2014; 109(3): 375-85.
[http://dx.doi.org/10.1038/ajg.2013.453] [PMID: 24419482]
[95]
Homko CJ, Duffy F, Friedenberg FK, Boden G, Parkman HP. Effect of dietary fat and food consistency on gastroparesis symptoms in patients with gastroparesis. Neurogastroenterol Motil 2015; 27(4): 501-8.
[http://dx.doi.org/10.1111/nmo.12519] [PMID: 25600163]
[96]
Wytiaz V, Homko C, Duffy F, Schey R, Parkman HP. Foods provoking and alleviating symptoms in gastroparesis: patient experiences. Dig Dis Sci 2015; 60(4): 1052-8.
[http://dx.doi.org/10.1007/s10620-015-3651-7] [PMID: 25840923]
[97]
Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes 2013; 4(3): 51-63.
[http://dx.doi.org/10.4239/wjd.v4.i3.51] [PMID: 23772273]
[98]
Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013; 108(1): 18-37.
[http://dx.doi.org/10.1038/ajg.2012.373] [PMID: 23147521]
[99]
Norton C, Cody JD. Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. Cochrane Database Syst Rev 2012; (7): CD002111.
[http://dx.doi.org/10.1002/14651858.CD002111.pub3] [PMID: 22786479]
[100]
Calles-Escandón J, Koch KL, Hasler WL, et al. Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: An open-label pilot prospective study. PLoS One 2018; 13(4): e0194759.
[http://dx.doi.org/10.1371/journal.pone.0194759] [PMID: 29652893]
[101]
Halland M, Bharucha AE. Relationship between control of glycemia and gastric emptying disturbances in diabetes mellitus. Clin Gastroenterol Hepatol 2016; 14(7): 929-36.
[http://dx.doi.org/10.1016/j.cgh.2015.11.021] [PMID: 26717862]
[102]
Petrakis IE, Vrachassotakis N, Sciacca V, Vassilakis SI, Chalkiadakis G. Hyperglycaemia attenuates erythromycin-induced acceleration of solid-phase gastric emptying in idiopathic and diabetic gastroparesis. Scand J Gastroenterol 1999; 34(4): 396-403.
[http://dx.doi.org/10.1080/003655299750026416] [PMID: 10365900]
[103]
Samsom M, Akkermans LM, Jebbink RJ, van Isselt H, vanBerge-Henegouwen GP, Smout AJ. Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus. Gut 1997; 40(5): 641-6.
[http://dx.doi.org/10.1136/gut.40.5.641] [PMID: 9203944]
[104]
Marathe CS, Marathe JA, Rayner CK, Kar P, Jones KL, Horowitz M. Hypoglycaemia and gastric emptying. Diabetes Obes Metab 2019; 21(3): 491-8.
[http://dx.doi.org/10.1111/dom.13570] [PMID: 30378748]
[105]
Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab 2018; 20(Suppl. 1): 5-21.
[http://dx.doi.org/10.1111/dom.13129] [PMID: 29364588]
[106]
Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not men, with diabetes: results of a phase 2b randomized study. Clin Gastroenterol Hepatol 2015; 13(7): 1256-1263.e1.
[http://dx.doi.org/10.1016/j.cgh.2014.12.030] [PMID: 25576687]
[107]
Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet. Neurogastroenterol Motil 2014; 26(4): 521-8.
[http://dx.doi.org/10.1111/nmo.12296] [PMID: 24372829]
[108]
Tack J, Carbone F. Functional dyspepsia and gastroparesis. Curr Opin Gastroenterol 2017; 33(6): 446-54.
[http://dx.doi.org/10.1097/MOG.0000000000000393] [PMID: 28832359]
[109]
Tomomasa T, Kuroume T, Arai H, Wakabayashi K, Itoh Z. Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci 1986; 31(2): 157-61.
[http://dx.doi.org/10.1007/BF01300701] [PMID: 3943442]
[110]
Cuomo R, Vandaele P, Coulie B, et al. Influence of motilin on gastric fundus tone and on meal-induced satiety in man: role of cholinergic pathways. Am J Gastroenterol 2006; 101(4): 804-11.
[http://dx.doi.org/10.1111/j.1572-0241.2005.00339.x] [PMID: 16635226]
[111]
Lin HC, Sanders SL, Gu YG, Doty JE. Erythromycin accelerates solid emptying at the expense of gastric sieving. Dig Dis Sci 1994; 39(1): 124-8.
[http://dx.doi.org/10.1007/BF02090071] [PMID: 8281846]
[112]
Arts J, Caenepeel P, Verbeke K, Tack J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 2005; 54(4): 455-60.
[http://dx.doi.org/10.1136/gut.2003.035279] [PMID: 15753526]
[113]
Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990; 322(15): 1028-31.
[http://dx.doi.org/10.1056/NEJM199004123221502] [PMID: 2320062]
[114]
Carbone F, Van den Houte K, Clevers E, et al. Prucalopride in gastroparesis: A randomized placebo-controlled crossover study. Am J Gastroenterol 2019; 114(8): 1265-74.
[http://dx.doi.org/10.14309/ajg.0000000000000304] [PMID: 31295161]
[115]
Midani D, Parkman HP. Granisetron transdermal system for treatment of symptoms of gastroparesis: A prescription registry study. J Neurogastroenterol Motil 2016; 22(4): 650-5.
[http://dx.doi.org/10.5056/jnm15203] [PMID: 27400689]
[116]
Simmons K, Parkman HP. Granisetron transdermal system improves refractory nausea and vomiting in gastroparesis. Dig Dis Sci 2014; 59(6): 1231-4.
[http://dx.doi.org/10.1007/s10620-014-3097-3] [PMID: 24615549]
[117]
Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA 2013; 310(24): 2640-9.
[http://dx.doi.org/10.1001/jama.2013.282833] [PMID: 24368464]
[118]
Talley NJ, Locke GR, Saito YA, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: A multicenter, randomized controlled study. Gastroenterology 2015; 149(2): 340-9.e2.
[http://dx.doi.org/10.1053/j.gastro.2015.04.020] [PMID: 25921377]
[119]
Malamood M, Roberts A, Kataria R, Parkman HP, Schey R. Mirtazapine for symptom control in refractory gastroparesis. Drug Des Devel Ther 2017; 11: 1035-41.
[http://dx.doi.org/10.2147/DDDT.S125743] [PMID: 28408802]
[120]
Rosa-e-Silva L, Troncon LE, Oliveira RB, Iazigi N, Gallo L Jr, Foss MC. Treatment of diabetic gastroparesis with oral clonidine. Aliment Pharmacol Ther 1995; 9(2): 179-83.
[http://dx.doi.org/10.1111/j.1365-2036.1995.tb00368.x] [PMID: 7605859]
[121]
Fragkos KC, Zárate-Lopez N, Frangos CC. What about clonidine for diarrhoea? A systematic review and meta-analysis of its effect in humans. Therap Adv Gastroenterol 2016; 9(3): 282-301.
[http://dx.doi.org/10.1177/1756283X15625586] [PMID: 27134659]
[122]
Sepulveda C, Real A, Nepomuceno J, Pimenta F. Autonomic enteropathy: A frequently ignored diabetic complication. Endocrinol Diabetes Nutr 2017; 64(6): 333-5.
[http://dx.doi.org/10.1016/j.endinu.2017.03.009] [PMID: 29056279]
[123]
Bilgutay AM, Wingrove R, Griffen WO, Bonnabeau RC Jr, Lillehei CW. Gastro-Intestinal Pacing: A New Concept in the Treatment of Ileus. Ann Surg 1963; 158: 338-48.
[http://dx.doi.org/10.1097/00000658-196315830-00003] [PMID: 14061702]
[124]
Eagon JC, Kelly KA. Effects of gastric pacing on canine gastric motility and emptying. Am J Physiol 1993; 265(4 Pt 1): G767-74.
[PMID: 8238360]
[125]
Levinthal DJ, Bielefeldt K. Systematic review and meta-analysis: Gastric electrical stimulation for gastroparesis. Auton Neurosci 2017; 202: 45-55.
[http://dx.doi.org/10.1016/j.autneu.2016.03.004] [PMID: 27085627]
[126]
Abell TL, Yamada G, McCallum RW, et al. Effectiveness of gastric electrical stimulation in gastroparesis: Results from a large prospectively collected database of national gastroparesis registries. Neurogastroenterol Motil 2019; 31(12): e13714.
[http://dx.doi.org/10.1111/nmo.13714] [PMID: 31584238]
[127]
O’Grady G, Egbuji JU, Du P, Cheng LK, Pullan AJ, Windsor JA. High-frequency gastric electrical stimulation for the treatment of gastroparesis: A meta-analysis. World J Surg 2009; 33(8): 1693-701.
[http://dx.doi.org/10.1007/s00268-009-0096-1] [PMID: 19506941]
[128]
Gourcerol G, Huet E, Vandaele N, et al. Long term efficacy of gastric electrical stimulation in intractable nausea and vomiting. Dig Liver Dis 2012; 44(7): 563-8.
[http://dx.doi.org/10.1016/j.dld.2012.01.013] [PMID: 22387288]
[129]
McCallum RW, Lin Z, Forster J, Roeser K, Hou Q, Sarosiek I. Gastric electrical stimulation improves outcomes of patients with gastroparesis for up to 10 years. Clin Gastroenterol Hepatol 2011; 9(4): 314-319.e1.
[http://dx.doi.org/10.1016/j.cgh.2010.12.013] [PMID: 21185396]
[130]
Bönhof GJ, Herder C, Strom A, Papanas N, Roden M, Ziegler D. Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr Rev 2019; 40(1): 153-92.
[http://dx.doi.org/10.1210/er.2018-00107] [PMID: 30256929]
[131]
Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012; 367(17): 1626-35.
[http://dx.doi.org/10.1056/NEJMra1207068] [PMID: 23094724]
[132]
Kindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 2006; 55(12): 1685-91.
[http://dx.doi.org/10.1136/gut.2005.085365] [PMID: 16854999]
[133]
Ervin CM, Reasner DS, Hanlon JT, Fehnel SE. Exploring the diabetic gastroparesis patient experience: patient exit interviews. Adv Ther 2017; 34(12): 2680-92.
[http://dx.doi.org/10.1007/s12325-017-0632-6] [PMID: 29079987]
[134]
Ford AC, Moayyedi P, Chey WD, et al. American college of gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol 2018; 113(Suppl. 2): 1-18.
[http://dx.doi.org/10.1038/s41395-018-0084-x] [PMID: 29950604]
[135]
Cangemi DJ, Lacy BE. Management of irritable bowel syndrome with diarrhea: A review of nonpharmacological and pharmacological interventions. Therap Adv Gastroenterol 2019; 12: 1756284819878950.
[http://dx.doi.org/10.1177/1756284819878950] [PMID: 31632456]
[136]
Johannesson E, Simrén M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: A randomized controlled trial. Am J Gastroenterol 2011; 106(5): 915-22.
[http://dx.doi.org/10.1038/ajg.2010.480] [PMID: 21206488]
[137]
Kim KH, Lee MS, Choi TY, Kim TH. Acupuncture for symptomatic gastroparesis. Cochrane Database Syst Rev 2018; 12: CD009676.
[PMID: 30560568]
[138]
Juel J, Liguori S, Liguori A, et al. Acupuncture for pain in chronic pancreatitis: A single-blinded randomized crossover trial. Pancreas 2017; 46(2): 170-6.
[http://dx.doi.org/10.1097/MPA.0000000000000749] [PMID: 28060186]
[139]
Sakamoto M, Matsutani D, Kayama Y. Clinical implications of baroreflex sensitivity in type 2 diabetes. Int Heart J 2019; 60(2): 241-6.
[http://dx.doi.org/10.1536/ihj.18-455] [PMID: 30799384]
[140]
Bernardi L, Rosengård-Bärlund M, Sandelin A, Mäkinen VP, Forsblom C, Groop PH. Short-term oxygen administration restores blunted baroreflex sensitivity in patients with type 1 diabetes. Diabetologia 2011; 54(8): 2164-73.
[http://dx.doi.org/10.1007/s00125-011-2195-4] [PMID: 21647699]
[141]
Esposito P, Mereu R, De Barbieri G, et al. Trained breathing-induced oxygenation acutely reverses cardiovascular autonomic dysfunction in patients with type 2 diabetes and renal disease. Acta Diabetol 2016; 53(2): 217-26.
[http://dx.doi.org/10.1007/s00592-015-0765-5] [PMID: 25956276]
[142]
Bhati P, Shenoy S, Hussain ME. Exercise training and cardiac autonomic function in type 2 diabetes mellitus: A systematic review. Diabetes Metab Syndr 2018; 12(1): 69-78.
[http://dx.doi.org/10.1016/j.dsx.2017.08.015] [PMID: 28888482]
[143]
Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes 1997; 46(Suppl. 2): S62-6.
[http://dx.doi.org/10.2337/diab.46.2.S62] [PMID: 9285502]
[144]
Lee SJ, Jeong SJ, Lee YC, et al. Effects of high-dose α-lipoic acid on heart rate variability of type 2 diabetes mellitus patients with cardiac autonomic neuropathy in Korea. Diabetes Metab J 2017; 41(4): 275-83.
[http://dx.doi.org/10.4093/dmj.2017.41.4.275] [PMID: 28868825]
[145]
Shotton HR, Broadbent S, Lincoln J. Prevention and partial reversal of diabetes-induced changes in enteric nerves of the rat ileum by combined treatment with alpha-lipoic acid and evening primrose oil. Auton Neurosci 2004; 111(1): 57-65.
[http://dx.doi.org/10.1016/j.autneu.2004.02.004] [PMID: 15109939]
[146]
Rivera LR, Poole DP, Thacker M, Furness JB. The involvement of nitric oxide synthase neurons in enteric neuropathies. Neurogastroenterol Motil 2011; 23(11): 980-8.
[http://dx.doi.org/10.1111/j.1365-2982.2011.01780.x] [PMID: 21895878]
[147]
Hermes-Uliana C, Frez FCV, Sehaber CC, et al. Supplementation with l-glutathione improves oxidative status and reduces protein nitration in myenteric neurons in the jejunum in diabetic Rattus norvegicus. Exp Mol Pathol 2018; 104(3): 227-34.
[http://dx.doi.org/10.1016/j.yexmp.2018.05.002] [PMID: 29758186]
[148]
Zanoni JN, Tronchini EA, Moure SA, Souza ID. Effects of L-glutamine supplementation on the myenteric neurons from the duodenum and cecum of diabetic rats. Arq Gastroenterol 2011; 48(1): 66-71.
[http://dx.doi.org/10.1590/S0004-28032011000100014] [PMID: 21537546]
[149]
Lupachyk S, Shevalye H, Maksimchyk Y, Drel VR, Obrosova IG. PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function. Free Radic Biol Med 2011; 50(10): 1400-9.
[http://dx.doi.org/10.1016/j.freeradbiomed.2011.01.037] [PMID: 21300148]
[150]
Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009; 32(8): 1479-84.
[http://dx.doi.org/10.2337/dc09-0545] [PMID: 19470838]
[151]
Ziegler D, Edmundson S, Gurieva I, Mankovsky B, Papanas N, Strokov I. Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy. J Diabetes Complications 2017; 31(7): 1181-7.
[http://dx.doi.org/10.1016/j.jdiacomp.2017.03.012] [PMID: 28438471]
[152]
Stirban A, Negrean M, Stratmann B, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006; 29(9): 2064-71.
[http://dx.doi.org/10.2337/dc06-0531] [PMID: 16936154]
[153]
Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9(3): 294-9.
[http://dx.doi.org/10.1038/nm834] [PMID: 12592403]
[154]
Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008; 116(10): 600-5.
[http://dx.doi.org/10.1055/s-2008-1065351] [PMID: 18473286]
[155]
Agrawal NK, Kant S. Targeting inflammation in diabetes: Newer therapeutic options. World J Diabetes 2014; 5(5): 697-710.
[http://dx.doi.org/10.4239/wjd.v5.i5.697] [PMID: 25317247]
[156]
Zhu T, Meng Q, Ji J, Lou X, Zhang L. Toll-like receptor 4 and tumor necrosis factor-alpha as diagnostic biomarkers for diabetic peripheral neuropathy. Neurosci Lett 2015; 585: 28-32.
[http://dx.doi.org/10.1016/j.neulet.2014.11.020] [PMID: 25445373]
[157]
Yamakawa I, Kojima H, Terashima T, et al. Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab 2011; 301(5): E844-52.
[http://dx.doi.org/10.1152/ajpendo.00029.2011] [PMID: 21810933]
[158]
Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: Antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2013; 38(8): 925-34.
[http://dx.doi.org/10.1111/apt.12479] [PMID: 24004101]
[159]
Shimozato A, Sasaki M, Ogasawara N, et al. Transglucosidase improves the bowel movements in type 2 diabetes mellitus patients: A preliminary randomized double-blind, placebo-controlled study. United European Gastroenterol J 2017; 5(6): 898-907.
[http://dx.doi.org/10.1177/2050640617692268] [PMID: 29026604]
[160]
De Giorgio R, Giancola F, Boschetti E, Abdo H, Lardeux B, Neunlist M. Enteric glia and neuroprotection: basic and clinical aspects. Am J Physiol Gastrointest Liver Physiol 2012; 303(8): G887-93.
[http://dx.doi.org/10.1152/ajpgi.00096.2012] [PMID: 22878122]
[161]
Sanger GJ, Broad J, Callaghan B, Furness JB. Ghrelin and motilin control systems in gi physiology and therapeutics. Handb Exp Pharmacol 2017; 239: 379-416.
[http://dx.doi.org/10.1007/164_2016_104] [PMID: 28035532]
[162]
Barton ME, Otiker T, Johnson LV, et al. 70 A randomized, double-blind, placebo-controlled phase ii study (mot114479) to evaluate the safety and efficacy and dose response of 28 days of orally administered camicinal, a motilin receptor agonist, in diabetics with gastroparesis. Gastroenterology 2014; 146(5): S-20.
[http://dx.doi.org/10.1016/S0016-5085(14)60070-6]
[163]
Hellström PM, Tack J, Johnson LV, et al. The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying. Br J Pharmacol 2016; 173(11): 1768-77.
[http://dx.doi.org/10.1111/bph.13475] [PMID: 26924243]
[164]
Camilleri M, Acosta A. A ghrelin agonist fails to show benefit in patients with diabetic gastroparesis: let’s not throw the baby out with the bath water. Neurogastroenterol Motil 2013; 25(11): 859-63.
[http://dx.doi.org/10.1111/nmo.12226] [PMID: 24001134]
[165]
Camilleri M, McCallum RW, Tack J, Spence SC, Gottesdiener K, Fiedorek FT. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: A randomized, placebo-controlled study. Gastroenterology 2017; 153(5): 1240-1250.e2.
[http://dx.doi.org/10.1053/j.gastro.2017.07.035] [PMID: 28760384]
[166]
Carlin J, Lieberman V, Dahal A, et al. Efficacy and safety of tradipitant in diabetic and idiopathic gastroparesis: A randomized, placebo-controlled study. 2021; 160(1): 76-87.
[167]
Pasricha PJ, Yates KP, Sarosiek I, et al. Aprepitant has mixed effects on nausea and reduces other symptoms in patients with gastroparesis and related disorders. Gastroenterology 2018; 154(1): 65-76.e11.
[http://dx.doi.org/10.1053/j.gastro.2017.08.033] [PMID: 29111115]
[168]
Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles. Neuropeptides 1998; 32(1): 1-49.
[http://dx.doi.org/10.1016/S0143-4179(98)90015-4] [PMID: 9571643]
[169]
Huang X, Lv B, Zhang S, Fan Y-H, Meng L-N. Itopride therapy for functional dyspepsia: A meta-analysis. World J Gastroenterol 2012; 18(48): 7371-7.
[http://dx.doi.org/10.3748/wjg.v18.i48.7371] [PMID: 23326147]
[170]
Calcutt NA, Smith DR, Frizzi K, et al. Selective antagonism of muscarinic receptors is neuroprotective in peripheral neuropathy. J Clin Invest 2017; 127(2): 608-22.
[http://dx.doi.org/10.1172/JCI88321] [PMID: 28094765]
[171]
Oduyebo I, Camilleri M, Nelson AD, et al. Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: A randomized phase 2 trial. Am J Gastroenterol 2018; 113(5): 725-34.
[http://dx.doi.org/10.1038/s41395-018-0042-7] [PMID: 29717197]
[172]
Sharma A, Coles M, Parkman HP. Gastroparesis in the 2020s: new treatments, new paradigms. Curr Gastroenterol Rep 2020; 22(5): 23.
[http://dx.doi.org/10.1007/s11894-020-00761-7] [PMID: 32193707]
[173]
Vijayvargiya P, Camilleri M. Use of prucalopride in adults with chronic idiopathic constipation. Expert Rev Clin Pharmacol 2019; 12(7): 579-89.
[http://dx.doi.org/10.1080/17512433.2019.1620104] [PMID: 31096799]
[174]
Bianco F, Bonora E, Natarajan D, et al. Prucalopride exerts neuroprotection in human enteric neurons. Am J Physiol Gastrointest Liver Physiol 2016; 310(10): G768-75.
[http://dx.doi.org/10.1152/ajpgi.00036.2016] [PMID: 26893157]
[175]
Abell T, Kuo B, Esfandyari T, et al. Velusetrag improves gastoparesis both in symptoms and gastric emptying in patients with diabetic or idiopathic gastroparesis in a 12-week global phase 2b study. Gastroenterology 2019; 156(6): S-164.
[http://dx.doi.org/10.1016/S0016-5085(19)37201-4]
[176]
Schoenfeld P, Lacy BE, Chey WD, et al. Low-dose linaclotide (72 μg) for chronic idiopathic constipation: A 12-week, randomized, double-blind, placebo-controlled Trial. Am J Gastroenterol 2018; 113(1): 105-14.
[http://dx.doi.org/10.1038/ajg.2017.230] [PMID: 29091082]
[177]
Quigley EM, Tack J, Chey WD, et al. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther 2013; 37(1): 49-61.
[http://dx.doi.org/10.1111/apt.12123] [PMID: 23116208]
[178]
Christie J, Shroff S, Shahnavaz N, et al. A randomized, double-blind, placebo-controlled trial to examine the effectiveness of lubiprostone on constipation symptoms and colon transit time in diabetic patients. Am J Gastroenterol 2017; 112(2): 356-64.
[http://dx.doi.org/10.1038/ajg.2016.531] [PMID: 27922028]
[179]
Lee TH, Lee JS. Ramosetron might be useful for treating diabetic diarrhea with a rapid small bowel transit time. Korean J Intern Med (Korean Assoc Intern Med) 2013; 28(1): 106-7.
[http://dx.doi.org/10.3904/kjim.2013.28.1.106] [PMID: 23346005]
[180]
Murao S, Hosokawa H. Serotonin 5-HT3 receptor antagonist for treatment of severe diabetic diarrhea. Diabetes Care 2010; 33(3): e38.
[http://dx.doi.org/10.2337/dc09-2131] [PMID: 20190286]
[181]
Black CJ, Burr NE, Camilleri M, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut 2020; 69(1): 74-82.
[http://dx.doi.org/10.1136/gutjnl-2018-318160] [PMID: 30996042]
[182]
Mourad FH, Gorard D, Thillainayagam AV, Colin-Jones D, Farthing MJ. Effective treatment of diabetic diarrhoea with somatostatin analogue, octreotide. Gut 1992; 33(11): 1578-80.
[http://dx.doi.org/10.1136/gut.33.11.1578] [PMID: 1452087]
[183]
Nakabayashi H, Fujii S, Miwa U, Seta T, Takeda R. Marked improvement of diabetic diarrhea with the somatostatin analogue octreotide. Arch Intern Med 1994; 154(16): 1863-7.
[http://dx.doi.org/10.1001/archinte.1994.00420160103014] [PMID: 8053756]
[184]
Valdovinos MA, Camilleri M, Zimmerman BR. Chronic diarrhea in diabetes mellitus: mechanisms and an approach to diagnosis and treatment. Mayo Clin Proc 1993; 68(7): 691-702.
[http://dx.doi.org/10.1016/S0025-6196(12)60606-5] [PMID: 8350642]
[185]
Kårhus ML, Brønden A, Røder ME, Leotta S, Sonne DP, Knop FK. Remission of bile acid malabsorption symptoms following treatment with the glucagon-like peptide 1 receptor agonist liraglutide. Gastroenterology 2019; 157(2): 569-71.
[http://dx.doi.org/10.1053/j.gastro.2019.04.002] [PMID: 30965026]
[186]
Valencia-Rodríguez A, Aquino-Matus J, Vera-Barajas A, Qi X, Méndez-Sánchez N. New therapeutic options for bile acid malabsorption diarrhea. Ann Transl Med 2019; 7(22): 695.
[http://dx.doi.org/10.21037/atm.2019.09.112] [PMID: 31930096]
[187]
Kobayashi M, Zochodne DW. Diabetic neuropathy and the sensory neuron: New aspects of pathogenesis and their treatment implications. J Diabetes Investig 2018; 9(6): 1239-54.
[http://dx.doi.org/10.1111/jdi.12833] [PMID: 29533535]
[188]
Erbil D, Eren CY, Demirel C, Küçüker MU, Solaroğlu I, Eser HY. GLP-1's role in neuroprotection: A systematic review. Brain Inj 2019; 33(6): 734-819.
[http://dx.doi.org/10.1080/02699052.2019.1587000] [PMID: 30938196]
[189]
Wegeberg AL, Hansen CS, Farmer AD, et al. Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial. United European Gastroenterol J 2020; 8(6): 695-704.
[http://dx.doi.org/10.1177/2050640620925968] [PMID: 32390563]
[190]
Jehangir A, Parkman HP. Cannabinoid use in patients with gastroparesis and related disorders: prevalence and benefit. Am J Gastroenterol 2019; 114(6): 945-53.
[http://dx.doi.org/10.14309/ajg.0000000000000181] [PMID: 30865015]
[191]
Camilleri M. Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterol Motil 2018; 30(9): e13370.
[http://dx.doi.org/10.1111/nmo.13370] [PMID: 29745439]
[192]
Barbash B, Mehta D, Siddiqui MT, Chawla L, Dworkin B. Impact of cannabinoids on symptoms of refractory gastroparesis: A single-center experience. Cureus 2019; 11(12): e6430.
[http://dx.doi.org/10.7759/cureus.6430] [PMID: 31993268]
[193]
McCallum RW, Chen JD, Lin Z, Schirmer BD, Williams RD, Ross RA. Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology 1998; 114(3): 456-61.
[http://dx.doi.org/10.1016/S0016-5085(98)70528-1] [PMID: 9496935]
[194]
Ducrotte P, Coffin B, Bonaz B, et al. Gastric electrical stimulation reduces refractory vomiting in a randomized crossover trial. Gastroenterology 2020; 158(3): 506-514.e2.
[http://dx.doi.org/10.1053/j.gastro.2019.10.018] [PMID: 31647902]
[195]
Alighaleh S, Cheng LK, Angeli TR, et al. A novel gastric pacing device to modulate slow waves and assessment by high-resolution mapping. IEEE Trans Biomed Eng 2019; 66(10): 2823-30.
[http://dx.doi.org/10.1109/TBME.2019.2896624] [PMID: 30735980]
[196]
Shada AL, Dunst CM, Pescarus R, et al. Laparoscopic pyloroplasty is a safe and effective first-line surgical therapy for refractory gastroparesis. Surg Endosc 2016; 30(4): 1326-32.
[http://dx.doi.org/10.1007/s00464-015-4385-5] [PMID: 26293794]
[197]
Sarosiek I, Forster J, Lin Z, Cherry S, Sarosiek J, McCallum R. The addition of pyloroplasty as a new surgical approach to enhance effectiveness of gastric electrical stimulation therapy in patients with gastroparesis. Neurogastroenterol Motil 2013; 25(2): 134-e80.
[http://dx.doi.org/10.1111/nmo.12032] [PMID: 23113904]
[198]
Davis BR, Sarosiek I, Bashashati M, Alvarado B, McCallum RW. The long-term efficacy and safety of pyloroplasty combined with gastric electrical stimulation therapy in gastroparesis. J Gastrointest Surg 2017; 21(2): 222-7.
[http://dx.doi.org/10.1007/s11605-016-3327-4] [PMID: 27896652]
[199]
Zoll B, Edwards MA, Petrov R, et al. Surgical interventions for refractory gastroparesis: gastric stimulator, pyloric surgery, or both? Gastroenterology 2019; 156(6): S-788.
[http://dx.doi.org/10.1016/S0016-5085(19)38922-X]
[200]
Khoury T, Mizrahi M, Mahamid M, et al. State of the art review with literature summary on gastric peroral endoscopic pyloromyotomy for gastroparesis. J Gastroenterol Hepatol 2018; 33(11): 1829-33.
[http://dx.doi.org/10.1111/jgh.14293] [PMID: 29806114]
[201]
Arts J, Holvoet L, Caenepeel P, et al. Clinical trial: A randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther 2007; 26(9): 1251-8.
[http://dx.doi.org/10.1111/j.1365-2036.2007.03467.x] [PMID: 17944739]
[202]
Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol 2008; 103(2): 416-23.
[http://dx.doi.org/10.1111/j.1572-0241.2007.01676.x] [PMID: 18070232]
[203]
Weusten BLAM, Barret M, Bredenoord AJ, et al. Endoscopic management of gastrointestinal motility disorders - part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2020; 52(6): 498-515.
[http://dx.doi.org/10.1055/a-1160-5549] [PMID: 32375192]
[204]
Rodriguez JH, Haskins IN, Strong AT, et al. Per oral endoscopic pyloromyotomy for refractory gastroparesis: initial results from a single institution. Surg Endosc 2017; 31(12): 5381-8.
[http://dx.doi.org/10.1007/s00464-017-5619-5] [PMID: 28567693]
[205]
Mohan BP, Chandan S, Jha LK, et al. Clinical efficacy of gastric per-oral endoscopic myotomy (G-POEM) in the treatment of refractory gastroparesis and predictors of outcomes: A systematic review and meta-analysis using surgical pyloroplasty as a comparator group. Surg Endosc 2020; 34(8): 3352-67.
[http://dx.doi.org/10.1007/s00464-019-07135-9] [PMID: 31583465]
[206]
Thompson JS, Hewlett A, Lyden E, Scott JR, McBride C. Patient factors influence surgical options in gastroparesis. Am J Surg 2020; 220(4): 1093-7.
[http://dx.doi.org/10.1016/j.amjsurg.2020.02.022] [PMID: 32102759]
[207]
Lee AM, Fuchs KH, Varga G, et al. Sleeve gastrectomy for treatment of delayed gastric emptying-indications, technique, and results. Langenbecks Arch Surg 2020; 405(1): 107-16.
[http://dx.doi.org/10.1007/s00423-020-01856-5] [PMID: 31956952]
[208]
Landreneau JP, Strong AT, El-Hayek K, Kroh MD, Rodriguez JH. Gastrectomy versus stomach left in situ with Roux-en-Y reconstruction for the treatment of gastroparesis. Surg Endosc 2020; 34(4): 1847-55.
[http://dx.doi.org/10.1007/s00464-019-06951-3] [PMID: 31297624]
[209]
Guerci B, Bourgeois C, Bresler L, Scherrer ML, Böhme P. Gastric electrical stimulation for the treatment of diabetic gastroparesis. Diabetes Metab 2012; 38(5): 393-402.
[http://dx.doi.org/10.1016/j.diabet.2012.05.001] [PMID: 22742875]
[210]
Yuan H, Silberstein SD. Vagus nerve and vagus nerve stimulation, a comprehensive review: part ii. Headache 2016; 56(2): 259-66.
[http://dx.doi.org/10.1111/head.12650] [PMID: 26381725]
[211]
Frøkjaer JB, Bergmann S, Brock C, et al. Modulation of vagal tone enhances gastroduodenal motility and reduces somatic pain sensitivity. Neurogastroenterol Motil 2016; 28(4): 592-8.
[http://dx.doi.org/10.1111/nmo.12760] [PMID: 26728182]
[212]
Paulon E, Nastou D, Jaboli F, Marin J, Liebler E, Epstein O. Proof of concept: short-term non-invasive cervical vagus nerve stimulation in patients with drug-refractory gastroparesis. Frontline Gastroenterol 2017; 8(4): 325-30.
[http://dx.doi.org/10.1136/flgastro-2017-100809] [PMID: 29067158]
[213]
Carroll SL, Byer SJ, Dorsey DA, Watson MA, Schmidt RE. Ganglion-specific patterns of diabetes-modulated gene expression are established in prevertebral and paravertebral sympathetic ganglia prior to the development of neuroaxonal dystrophy. J Neuropathol Exp Neurol 2004; 63(11): 1144-54.
[http://dx.doi.org/10.1093/jnen/63.11.1144] [PMID: 15581182]
[214]
Guo C, Quobatari A, Shangguan Y, Hong S, Wiley JW. Diabetic autonomic neuropathy: evidence for apoptosis in situ in the rat. Neurogastroenterol Motil 2004; 16(3): 335-45.
[http://dx.doi.org/10.1111/j.1365-2982.2004.00524.x] [PMID: 15198656]
[215]
Tay SS, Wong WC. Short- and long-term effects of streptozotocin-induced diabetes on the dorsal motor nucleus of the vagus nerve in the rat. Acta Anat (Basel) 1994; 150(4): 274-81.
[http://dx.doi.org/10.1159/000147630] [PMID: 7839795]
[216]
Yan B, Li L, Harden SW, Epstein PN, Wurster RD, Cheng ZJ. Diabetes induces neural degeneration in nucleus ambiguus (NA) and attenuates heart rate control in OVE26 mice. Exp Neurol 2009; 220(1): 34-43.
[http://dx.doi.org/10.1016/j.expneurol.2009.07.006] [PMID: 19615367]
[217]
Boychuk CR, Smith KC, Smith BN. Functional and molecular plasticity of γ and α1 GABAA receptor subunits in the dorsal motor nucleus of the vagus after experimentally induced diabetes. J Neurophysiol 2017; 118(5): 2833-41.
[http://dx.doi.org/10.1152/jn.00085.2017] [PMID: 28835522]
[218]
Lamy CM, Sanno H, Labouèbe G, et al. Hypoglycemia-activated GLUT2 neurons of the nucleus tractus solitarius stimulate vagal activity and glucagon secretion. Cell Metab 2014; 19(3): 527-38.
[http://dx.doi.org/10.1016/j.cmet.2014.02.003] [PMID: 24606905]
[219]
Forster J, Damjanov I, Lin Z, Sarosiek I, Wetzel P, McCallum RW. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J Gastrointest Surg 2005; 9(1): 102-8.
[http://dx.doi.org/10.1016/j.gassur.2004.10.001] [PMID: 15623450]
[220]
Botha C, Farmer AD, Nilsson M, et al. Preliminary report: modulation of parasympathetic nervous system tone influences oesophageal pain hypersensitivity. Gut 2015; 64(4): 611-7.
[http://dx.doi.org/10.1136/gutjnl-2013-306698] [PMID: 24870622]
[221]
Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus and inflammation. Curr Diab Rep 2013; 13(3): 435-44.
[http://dx.doi.org/10.1007/s11892-013-0375-y] [PMID: 23494755]
[222]
Kwan H, Garzoni L, Liu HL, et al. Vagus nerve stimulation for treatment of inflammation: systematic review of animal models and clinical studies. Bioelectron Med 2016; 3: 1-6.
[http://dx.doi.org/10.15424/bioelectronmed.2016.00005] [PMID: 29308423]
[223]
Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci USA 2016; 113(29): 8284-9.
[http://dx.doi.org/10.1073/pnas.1605635113] [PMID: 27382171]
[224]
Uvnäs-Moberg K. Release of gastrointestinal peptides in response to vagal activation induced by electrical stimulation, feeding and suckling. J Auton Nerv Syst 1983; 9(1): 141-55.
[http://dx.doi.org/10.1016/0165-1838(83)90137-6] [PMID: 6141200]
[225]
Madaus S, Bender H, Schusdziarra V, et al. Vagally induced release of gastrin, somatostatin and bombesin-like immunoreactivity from perfused rat stomach. Effect of stimulation frequency and cholinergic mechanisms. Regul Pept 1990; 30(3): 179-92.
[http://dx.doi.org/10.1016/0167-0115(90)90093-C] [PMID: 1979685]
[226]
Brock C, Brock B, Pedersen AG, Drewes AM, Jessen N, Farmer AD. Assessment of the cardiovascular and gastrointestinal autonomic complications of diabetes. World J Diabetes 2016; 7(16): 321-32.
[http://dx.doi.org/10.4239/wjd.v7.i16.321] [PMID: 27625746]

Rights & Permissions Print Cite
Article Metrics
25
1
© 2024 Bentham Science Publishers | Privacy Policy